Rotolo Federico - Biostatistics and Data Management, Innate Pharma

基本信息

浏览量：43

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 60 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

303P Predicting Quality of Life Trajectories in Young Women with Breast Cancer: 5-Year Results from a Large Prospective Cohort

B.F. Vaca-Cartagena, A.S. Ferrigno Guajardo,H.A. Azim,F. Rotolo, A. Olivas-Martinez,A. Platas, A. Fonseca,F. Mesa-Chavez,M. Cruz Ramos, A. Rodríguez, A. Mohar,C. Villarreal-Garza

Annals of Oncology (2024)

引用0浏览0引用

CO2.2 - Analyse De La Durée De Réponse Dans Les Essais De Phase II En Cancérologie : Une Étude De Simulation

S. Cyrille, C. Jiang,A. Latouche,F. Rotolo,X. Paoletti

Journal of Epidemiology and Population Health (2024)

引用0浏览0引用

823O Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell engager (NKCE) SAR443579 in patients (pts) with relapsed or refractory acute myeloid leukemia (R/R AML), B cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS)

M. Jongen-Lavrencic,A. Bajel,S. Garciaz, A. Maiti, S. Fleming, S. De Button,G.A. Huls, K. Jensen, S. Ziti-Ljajic, D. Draganov,F. Rotolo, C. Palu, J. Courta, W. Passe-Coutrin, K. Traudtner, T. Wagenaar,G. Abbadessa, A. Selwyn Stein

Annals of Oncology（2023）

引用0浏览0引用

Favoring the Hierarchical Constraint in Penalized Survival Models for Randomized Trials in Precision Medicine

Shaima Belhechmi,Gwénaël Le Teuff,Riccardo De Bin,Federico Rotolo,Stefan Michiels

BMC Bioinformaticsno. 1 (2023)

引用0浏览0WOSEI引用

Joint Modeling of Safety and Peripheral Mode-of-action (moa) Biomarkers to Support RP2D Identification in Phase 1 Study of SAR444245 (SAR'245) As Monotherapy (mono) or Combined with Pembrolizumab (pembro) in Patients with Advanced Solid Tumors

Siqing Fu,Gerald S. Falchook,Minal Barve,Meredith McKean,Tira J. Tan,Charlotte Lemech,Cheng E. Chee,Neyssa Marina,Giovanni Abbadessa,Robin Meng,Federico Rotolo,Hong Wang, Jason Deng, Wenting Wang,Rui Wang,Tarek Meniawy

CANCER RESEARCHno. 7 (2023)

引用0浏览0引用

Temps Passé En Réponse: Un Nouveau Critère Pour L’évaluation De L'activité Dans Les Maladies Avancées En Cancérologie

C. Jiang,F. Rotolo,A. Leary,A. Latouche,X. Paoletti

Revue d'Épidémiologie et de Santé Publique (2022): S76

引用0浏览0引用

123MO Monalizumab, Cetuximab and Durvalumab in First-Line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): A Phase II Trial

D. A. Colevas,K. Misiukiewicz,A. T. Pearson,J. Fayette,J. R. Bauman,D. Cupissol,E. Saada-Bouzid,D. R. Adkins, D. B. Marie, S. L. Cornen, P. Andre, F. Carrette,F. Rotolo,A. Boyer Chammard,R. B. Cohen

Annals of oncology（2021）

引用7浏览0引用

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Robert J. Kreitman,Claire Dearden,Pier Luigi Zinzani,Julio Delgado,Tadeusz Robak,Philipp D. le Coutre,Bjørn T. Gjertsen,Xavier Troussard,Gail J. Roboz,Lionel Karlin,Douglas E. Gladstone,Nataliya Kuptsova-Clarkson,Shiyao Liu,Priti Patel,Federico Rotolo, Emmanuel Mitry,Ira Pastan,Francis Giles

JOURNAL OF HEMATOLOGY & ONCOLOGYno. 1 (2021): 35-11

引用45浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn